FDA Grants Ebvallo a Second Look After Agreement With Regulators
TL;DR Summary
Two drugmakers say the FDA has agreed that Ebvallo’s single-arm trial can support a new review for a rare blood cancer, reversing the agency’s earlier finding that the data were insufficient; a late-April meeting with regulators occurred as Vinay Prasad departed the agency, paving a potential path to approval.
- FDA to reconsider treatment for rare cancer after its surprise rejection statnews.com
- Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel Business Wire
- FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next? Fierce Pharma
- Pierre Fabre Pharmaceuticals Announces Regulatory Update Following Type A Meeting with U.S. Food and Drug Administration (FDA) on Tabelecleucel Biologic License Application (BLA) PR Newswire
- FDA reverses course on Atara, Pierre Fabre’s twice-rejected cell therapy after Prasad’s exit BioSpace
Reading Insights
Total Reads
0
Unique Readers
16
Time Saved
2 min
vs 3 min read
Condensed
90%
497 → 49 words
Want the full story? Read the original article
Read on statnews.com